期刊
DRUG DISCOVERY TODAY
卷 24, 期 5, 页码 1193-1201出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2019.03.008
关键词
-
资金
- Brain Tumour Charity (UK) [GN-000429]
Glioblastoma (GBM) remains one of the most intransigent of cancers, with a median overall survival of only 15 months after diagnosis. Drug treatments have largely proven ineffective; it is thought that this is related to the heterogeneous nature and plasticity of GBM-initiating stem cell lineages. Although many combination drug therapies are being positioned to address tumour heterogeneity, the most promising therapeutic approaches for GBM to date appear to be those targeting GBM by vaccination or antibody and cell-based immunotherapy. We review the most recent clinical trials for GBM and discuss the role of adaptive clinical trials in developing personalised treatment strategies to address intra- and intert-umoral heterogeneity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据